Hikma gave a profit warning disguised in the form of a trading update (revealing only top-line numbers) ahead of its half-yearly results due on 24 August 2016. In H1 16, total revenue (excluding other income) came in at $877m, up 24% yoy, benefiting from the inclusion of four months’ contribution from the Roxane acquisition, now called West-Ward Columbus (excluding Roxane, revenue was down c.3.5% yoy). This came slightly below consensus estimates, mainly due to lower-than-expected reven
12 Aug 2016
Roxane hiccup triggers guidance downgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Roxane hiccup triggers guidance downgrade
Hikma Pharmaceuticals Plc (HIK:LON) | 1,926 0 0.0% | Mkt Cap: 4,274m
- Published:
12 Aug 2016 -
Author:
Jyoti Prakash -
Pages:
3
Hikma gave a profit warning disguised in the form of a trading update (revealing only top-line numbers) ahead of its half-yearly results due on 24 August 2016. In H1 16, total revenue (excluding other income) came in at $877m, up 24% yoy, benefiting from the inclusion of four months’ contribution from the Roxane acquisition, now called West-Ward Columbus (excluding Roxane, revenue was down c.3.5% yoy). This came slightly below consensus estimates, mainly due to lower-than-expected reven